Attività scientifica

Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea – JCI Insight - Mylonas A, Hawerkamp HC, Wang Y, Chen J, Messina F, Demaria O, Meller S, Homey B, Di Domizio J, Mazzolai L, Hovnanian A, Gilliet M, Conrad C

Abstract: 1569 A specific inflammatory gene signature in pityriasis rubra pilaris identifies a pathogenic role for keratinocytes – Journal of Investigative Dermatology - Messina F, Yatim A, Di Domizio J, Chen J, Guenova E, Hoetzenecker W, Schlapbach C, Gilliet M, Conrad C

Abstract: 020 Cytokine imbalance during targeted therapies for psoriasis and atopic dermatitis the yin yang of Th17 and Th2- Journal of Investigative Dermatology - Messina F, Nidegger A, Di Domizio J, Caplanusi T, Guenova E, Gilliet M, Conrad C

The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition – Journal of Dermatological Treatment - F Messina, S Piaserico 

Pharmacological management of severe plaque psoriasis in patients with cardiovascular disease – Expert Opinion on Pharmacotherapy - S. Piaserico, F. Messina 

Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study – Dermatology - A Ortolan, M Lorenzin, G Leo, F Pampaloni, F Messina, A Doria, S Piaserico, R Ramonda 

Trauma of Peripheral Innervation Impairs Content of Epidermal Langerhans Cells – Diagnostics - G Albertin, B Ravara, H Kern, S Zampieri, S Loefler, C Hofer, D Guidolin, F Messina, R De Caro, M Alaibac, U Carraro

Early predictors of psoriatic arthritis: a delphi based consensus from Italian dermatology centers – Italian Journal of Dermatology and Venereology - F Messina, M Valenti, P Malagoli, A Dattola, P Gisondi, M Burlando, P Dapavo, V Dini, C Franchi, F Loconsole, M Megna, A Costanzo

Efficacy and safety of guselkumab in two psoriatic patients with hepatitis B and C virus infection – Dermatologic Therapy - F Messina, F Peccerillo, G Odorici, A Conti, S Piaserico

Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis – BioDrugs - S Piaserico, A Conti, F Messina, A Meneguzzo, G Odorici, F Bellinato, P Gisondi 

Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues – Immunotherapy - M Ferranti, G Tadiotto Cicogna, F Messina, M Alaibac 

Association between melanoma and exposure to sex hormones in puberty: A possible window of susceptibility (Review) – Molecular and Clinical Oncology - F Caroppo, G Tadiotto Cicogna, F Messina, M Alaibac 

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study – American Journal of Clinical Dermatology - T Torres, L Puig, R Vender , C Lynde, S Piaserico, J M Carrascosa, P Gisondi, E Daudén, C Conrad, P Mendes-Bastos, P Ferreira, L Leite, J D Lu, J Valerio, M Bruni, F Messina, A Nidegger, M Llamas-Velasco, E Del Alcazar, A Mufti, K White, G Caldarola, L Teixeira, P Romanelli, K Desai, S Gkalpakiotis, M Romanelli, J Yeung, M Nogueira, A Chiricozzi

Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience
– J Allergy Clin Immunol - P Gisondi, S Piaserico, L Naldi, P Dapavo, A Conti, P Malagoli, A V Marzano, F Bardazzi, M Gasperini, S Cazzaniga, A Costanzo, collaborators in the studies of COVID-19 pandemic (L Sacchelli, E Pezzolo, F Messina, C Lasagni, L Bigi, A Cattaneo, C G Carrera, L Arancio, S Ribero, G Rozzo, G Damiani, P Facheris) 

Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNFalpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'
– Ann Rheum Dis - F Messina, F Pampaloni, S Piaserico

REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19 – J Infect - S Piaserico, A Meneguzzo, F Messina

SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐23 inhibitor – J Eur Acad Dermatol Venereol - F Messina, S Piaserico .

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: Results from a European, multicentric, retrospective, realworld study. – J Dermatolog Treat - A Chiricozzi, A Balato, C Conrad, A Conti, P Dapavo, P Ferreira, F M Gaiani, L Leite, P Malagoli, P Mendes- Bastos, M Megna, F Messina, A Nidegger, G Odorici, S Panduri, S Piaserico, L Piscitelli, F Prignano, S Ribero, J Valerio, T Torres

Osteoporotic vertebral fracture caused by topical corticosteroid abuse: A case report – Experimental and Therapeutic Medicine - S Piaserico, D Linder, F Messina, M Alaibac

Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. – J Am Acad Dermatol - T Torres, A Balato, C Conrad, A Conti, P Dapavo, P Ferreira, F Gaiani, L Leite, P Malagoli, P Mendes-Bastos, M Megna, F Messina, A Nidegger, G Odorici, S Piaserico, F Prignano, S Ribero, F Ricceri, A Tonini, J Valério, A Chiricozzi

Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. – Am J Clin Dermatol - S Piaserico, F Messina, F P Russo

 Case Report: Paradoxical acrodermatitis of Hallopeau-like eruption following anti-IL-17 therapy. – F1000Res - G Tadiotto Cicogna, F Messina, L Nalotto, S Szekely, M Alaibac​